PMC:7589163 / 52509-53871 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T274","span":{"begin":53,"end":64},"obj":"Body_part"},{"id":"T275","span":{"begin":125,"end":142},"obj":"Body_part"},{"id":"T276","span":{"begin":479,"end":492},"obj":"Body_part"},{"id":"T277","span":{"begin":682,"end":705},"obj":"Body_part"},{"id":"T278","span":{"begin":1211,"end":1216},"obj":"Body_part"},{"id":"T279","span":{"begin":1332,"end":1355},"obj":"Body_part"}],"attributes":[{"id":"A274","pred":"fma_id","subj":"T274","obj":"http://purl.org/sig/ont/fma/fma82738"},{"id":"A275","pred":"fma_id","subj":"T275","obj":"http://purl.org/sig/ont/fma/fma265130"},{"id":"A276","pred":"fma_id","subj":"T276","obj":"http://purl.org/sig/ont/fma/fma76497"},{"id":"A277","pred":"fma_id","subj":"T277","obj":"http://purl.org/sig/ont/fma/fma45662"},{"id":"A278","pred":"fma_id","subj":"T278","obj":"http://purl.org/sig/ont/fma/fma9670"},{"id":"A279","pred":"fma_id","subj":"T279","obj":"http://purl.org/sig/ont/fma/fma45662"}],"text":"Some studies investigated the effects of the omega-3 fatty acids supplementation on infant morbidity, particularly caused by respiratory tract infections, wheezing, and asthma. Imhoff et al. showed that DHA supplementation during pregnancy decreased the occurrence of colds in children at 1 month and influenced illness symptom duration [213]. Pastor et al. in a multicenter, prospective, open-label observational study, which included 1342 infants, showed a higher incidence of bronchiolitis in control versus groups who received omega-3-supplemented formula [214]. In contrast, in another study aimed to valuate the effect of neonatal DHA supplementation, the hospitalisation for lower respiratory tract problems in the first 18 months for preterm infants was not reduced [215]. A randomized controlled, trial which included 736 pregnant women and a total of 695 children, showed that the risk of persistent wheeze or asthma was reduced by approximately 7% in the first 5 years of life among children of women who received daily supplementation with omega−3 PUFA (EPA/DHA) during the third trimester of pregnancy. It is notable that this effect was most prominent among children of women with low EPA and DHA blood levels at randomization. Furthermore, supplementation was also associated with a reduced risk of infections of the lower respiratory tract [216]."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T95","span":{"begin":125,"end":142},"obj":"Body_part"},{"id":"T96","span":{"begin":682,"end":705},"obj":"Body_part"},{"id":"T97","span":{"begin":688,"end":705},"obj":"Body_part"},{"id":"T98","span":{"begin":1211,"end":1216},"obj":"Body_part"},{"id":"T99","span":{"begin":1332,"end":1355},"obj":"Body_part"},{"id":"T100","span":{"begin":1338,"end":1355},"obj":"Body_part"}],"attributes":[{"id":"A95","pred":"uberon_id","subj":"T95","obj":"http://purl.obolibrary.org/obo/UBERON_0000065"},{"id":"A96","pred":"uberon_id","subj":"T96","obj":"http://purl.obolibrary.org/obo/UBERON_0001558"},{"id":"A97","pred":"uberon_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/UBERON_0000065"},{"id":"A98","pred":"uberon_id","subj":"T98","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"A99","pred":"uberon_id","subj":"T99","obj":"http://purl.obolibrary.org/obo/UBERON_0001558"},{"id":"A100","pred":"uberon_id","subj":"T100","obj":"http://purl.obolibrary.org/obo/UBERON_0000065"}],"text":"Some studies investigated the effects of the omega-3 fatty acids supplementation on infant morbidity, particularly caused by respiratory tract infections, wheezing, and asthma. Imhoff et al. showed that DHA supplementation during pregnancy decreased the occurrence of colds in children at 1 month and influenced illness symptom duration [213]. Pastor et al. in a multicenter, prospective, open-label observational study, which included 1342 infants, showed a higher incidence of bronchiolitis in control versus groups who received omega-3-supplemented formula [214]. In contrast, in another study aimed to valuate the effect of neonatal DHA supplementation, the hospitalisation for lower respiratory tract problems in the first 18 months for preterm infants was not reduced [215]. A randomized controlled, trial which included 736 pregnant women and a total of 695 children, showed that the risk of persistent wheeze or asthma was reduced by approximately 7% in the first 5 years of life among children of women who received daily supplementation with omega−3 PUFA (EPA/DHA) during the third trimester of pregnancy. It is notable that this effect was most prominent among children of women with low EPA and DHA blood levels at randomization. Furthermore, supplementation was also associated with a reduced risk of infections of the lower respiratory tract [216]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T203","span":{"begin":125,"end":153},"obj":"Disease"},{"id":"T204","span":{"begin":169,"end":175},"obj":"Disease"},{"id":"T205","span":{"begin":479,"end":492},"obj":"Disease"},{"id":"T206","span":{"begin":920,"end":926},"obj":"Disease"},{"id":"T207","span":{"begin":1314,"end":1324},"obj":"Disease"}],"attributes":[{"id":"A203","pred":"mondo_id","subj":"T203","obj":"http://purl.obolibrary.org/obo/MONDO_0024355"},{"id":"A204","pred":"mondo_id","subj":"T204","obj":"http://purl.obolibrary.org/obo/MONDO_0004979"},{"id":"A205","pred":"mondo_id","subj":"T205","obj":"http://purl.obolibrary.org/obo/MONDO_0002465"},{"id":"A206","pred":"mondo_id","subj":"T206","obj":"http://purl.obolibrary.org/obo/MONDO_0004979"},{"id":"A207","pred":"mondo_id","subj":"T207","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Some studies investigated the effects of the omega-3 fatty acids supplementation on infant morbidity, particularly caused by respiratory tract infections, wheezing, and asthma. Imhoff et al. showed that DHA supplementation during pregnancy decreased the occurrence of colds in children at 1 month and influenced illness symptom duration [213]. Pastor et al. in a multicenter, prospective, open-label observational study, which included 1342 infants, showed a higher incidence of bronchiolitis in control versus groups who received omega-3-supplemented formula [214]. In contrast, in another study aimed to valuate the effect of neonatal DHA supplementation, the hospitalisation for lower respiratory tract problems in the first 18 months for preterm infants was not reduced [215]. A randomized controlled, trial which included 736 pregnant women and a total of 695 children, showed that the risk of persistent wheeze or asthma was reduced by approximately 7% in the first 5 years of life among children of women who received daily supplementation with omega−3 PUFA (EPA/DHA) during the third trimester of pregnancy. It is notable that this effect was most prominent among children of women with low EPA and DHA blood levels at randomization. Furthermore, supplementation was also associated with a reduced risk of infections of the lower respiratory tract [216]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T520","span":{"begin":286,"end":290},"obj":"http://purl.obolibrary.org/obo/CLO_0001757"},{"id":"T521","span":{"begin":361,"end":362},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T522","span":{"begin":394,"end":399},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T523","span":{"begin":457,"end":458},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T524","span":{"begin":479,"end":492},"obj":"http://purl.obolibrary.org/obo/UBERON_0002186"},{"id":"T525","span":{"begin":682,"end":705},"obj":"http://purl.obolibrary.org/obo/UBERON_0001558"},{"id":"T526","span":{"begin":728,"end":730},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T527","span":{"begin":781,"end":782},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T528","span":{"begin":850,"end":851},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T529","span":{"begin":1211,"end":1216},"obj":"http://purl.obolibrary.org/obo/UBERON_0000178"},{"id":"T530","span":{"begin":1211,"end":1216},"obj":"http://www.ebi.ac.uk/efo/EFO_0000296"},{"id":"T531","span":{"begin":1296,"end":1297},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T532","span":{"begin":1332,"end":1355},"obj":"http://purl.obolibrary.org/obo/UBERON_0001558"}],"text":"Some studies investigated the effects of the omega-3 fatty acids supplementation on infant morbidity, particularly caused by respiratory tract infections, wheezing, and asthma. Imhoff et al. showed that DHA supplementation during pregnancy decreased the occurrence of colds in children at 1 month and influenced illness symptom duration [213]. Pastor et al. in a multicenter, prospective, open-label observational study, which included 1342 infants, showed a higher incidence of bronchiolitis in control versus groups who received omega-3-supplemented formula [214]. In contrast, in another study aimed to valuate the effect of neonatal DHA supplementation, the hospitalisation for lower respiratory tract problems in the first 18 months for preterm infants was not reduced [215]. A randomized controlled, trial which included 736 pregnant women and a total of 695 children, showed that the risk of persistent wheeze or asthma was reduced by approximately 7% in the first 5 years of life among children of women who received daily supplementation with omega−3 PUFA (EPA/DHA) during the third trimester of pregnancy. It is notable that this effect was most prominent among children of women with low EPA and DHA blood levels at randomization. Furthermore, supplementation was also associated with a reduced risk of infections of the lower respiratory tract [216]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T58954","span":{"begin":45,"end":64},"obj":"Chemical"},{"id":"T5515","span":{"begin":53,"end":64},"obj":"Chemical"},{"id":"T92728","span":{"begin":59,"end":64},"obj":"Chemical"},{"id":"T72908","span":{"begin":203,"end":206},"obj":"Chemical"},{"id":"T8053","span":{"begin":394,"end":399},"obj":"Chemical"},{"id":"T90045","span":{"begin":637,"end":640},"obj":"Chemical"},{"id":"T81148","span":{"begin":1060,"end":1064},"obj":"Chemical"},{"id":"T36825","span":{"begin":1066,"end":1069},"obj":"Chemical"},{"id":"T16119","span":{"begin":1070,"end":1073},"obj":"Chemical"},{"id":"T91570","span":{"begin":1199,"end":1202},"obj":"Chemical"},{"id":"T48796","span":{"begin":1207,"end":1210},"obj":"Chemical"}],"attributes":[{"id":"A72414","pred":"chebi_id","subj":"T58954","obj":"http://purl.obolibrary.org/obo/CHEBI_25681"},{"id":"A41855","pred":"chebi_id","subj":"T5515","obj":"http://purl.obolibrary.org/obo/CHEBI_35366"},{"id":"A2452","pred":"chebi_id","subj":"T92728","obj":"http://purl.obolibrary.org/obo/CHEBI_37527"},{"id":"A62523","pred":"chebi_id","subj":"T72908","obj":"http://purl.obolibrary.org/obo/CHEBI_16016"},{"id":"A9633","pred":"chebi_id","subj":"T72908","obj":"http://purl.obolibrary.org/obo/CHEBI_28125"},{"id":"A2673","pred":"chebi_id","subj":"T72908","obj":"http://purl.obolibrary.org/obo/CHEBI_28689"},{"id":"A80218","pred":"chebi_id","subj":"T72908","obj":"http://purl.obolibrary.org/obo/CHEBI_36005"},{"id":"A57661","pred":"chebi_id","subj":"T8053","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A55835","pred":"chebi_id","subj":"T90045","obj":"http://purl.obolibrary.org/obo/CHEBI_16016"},{"id":"A20918","pred":"chebi_id","subj":"T90045","obj":"http://purl.obolibrary.org/obo/CHEBI_28125"},{"id":"A25897","pred":"chebi_id","subj":"T90045","obj":"http://purl.obolibrary.org/obo/CHEBI_28689"},{"id":"A44643","pred":"chebi_id","subj":"T90045","obj":"http://purl.obolibrary.org/obo/CHEBI_36005"},{"id":"A43343","pred":"chebi_id","subj":"T81148","obj":"http://purl.obolibrary.org/obo/CHEBI_26208"},{"id":"A31060","pred":"chebi_id","subj":"T81148","obj":"http://purl.obolibrary.org/obo/CHEBI_76567"},{"id":"A97748","pred":"chebi_id","subj":"T36825","obj":"http://purl.obolibrary.org/obo/CHEBI_28364"},{"id":"A37565","pred":"chebi_id","subj":"T16119","obj":"http://purl.obolibrary.org/obo/CHEBI_16016"},{"id":"A5647","pred":"chebi_id","subj":"T16119","obj":"http://purl.obolibrary.org/obo/CHEBI_28125"},{"id":"A2894","pred":"chebi_id","subj":"T16119","obj":"http://purl.obolibrary.org/obo/CHEBI_28689"},{"id":"A97211","pred":"chebi_id","subj":"T16119","obj":"http://purl.obolibrary.org/obo/CHEBI_36005"},{"id":"A13255","pred":"chebi_id","subj":"T91570","obj":"http://purl.obolibrary.org/obo/CHEBI_28364"},{"id":"A69417","pred":"chebi_id","subj":"T48796","obj":"http://purl.obolibrary.org/obo/CHEBI_16016"},{"id":"A84164","pred":"chebi_id","subj":"T48796","obj":"http://purl.obolibrary.org/obo/CHEBI_28125"},{"id":"A29079","pred":"chebi_id","subj":"T48796","obj":"http://purl.obolibrary.org/obo/CHEBI_28689"},{"id":"A44987","pred":"chebi_id","subj":"T48796","obj":"http://purl.obolibrary.org/obo/CHEBI_36005"}],"text":"Some studies investigated the effects of the omega-3 fatty acids supplementation on infant morbidity, particularly caused by respiratory tract infections, wheezing, and asthma. Imhoff et al. showed that DHA supplementation during pregnancy decreased the occurrence of colds in children at 1 month and influenced illness symptom duration [213]. Pastor et al. in a multicenter, prospective, open-label observational study, which included 1342 infants, showed a higher incidence of bronchiolitis in control versus groups who received omega-3-supplemented formula [214]. In contrast, in another study aimed to valuate the effect of neonatal DHA supplementation, the hospitalisation for lower respiratory tract problems in the first 18 months for preterm infants was not reduced [215]. A randomized controlled, trial which included 736 pregnant women and a total of 695 children, showed that the risk of persistent wheeze or asthma was reduced by approximately 7% in the first 5 years of life among children of women who received daily supplementation with omega−3 PUFA (EPA/DHA) during the third trimester of pregnancy. It is notable that this effect was most prominent among children of women with low EPA and DHA blood levels at randomization. Furthermore, supplementation was also associated with a reduced risk of infections of the lower respiratory tract [216]."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T97","span":{"begin":125,"end":153},"obj":"Phenotype"},{"id":"T98","span":{"begin":155,"end":163},"obj":"Phenotype"},{"id":"T99","span":{"begin":169,"end":175},"obj":"Phenotype"},{"id":"T100","span":{"begin":479,"end":492},"obj":"Phenotype"},{"id":"T101","span":{"begin":920,"end":926},"obj":"Phenotype"}],"attributes":[{"id":"A97","pred":"hp_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/HP_0011947"},{"id":"A98","pred":"hp_id","subj":"T98","obj":"http://purl.obolibrary.org/obo/HP_0030828"},{"id":"A99","pred":"hp_id","subj":"T99","obj":"http://purl.obolibrary.org/obo/HP_0002099"},{"id":"A100","pred":"hp_id","subj":"T100","obj":"http://purl.obolibrary.org/obo/HP_0011950"},{"id":"A101","pred":"hp_id","subj":"T101","obj":"http://purl.obolibrary.org/obo/HP_0002099"}],"text":"Some studies investigated the effects of the omega-3 fatty acids supplementation on infant morbidity, particularly caused by respiratory tract infections, wheezing, and asthma. Imhoff et al. showed that DHA supplementation during pregnancy decreased the occurrence of colds in children at 1 month and influenced illness symptom duration [213]. Pastor et al. in a multicenter, prospective, open-label observational study, which included 1342 infants, showed a higher incidence of bronchiolitis in control versus groups who received omega-3-supplemented formula [214]. In contrast, in another study aimed to valuate the effect of neonatal DHA supplementation, the hospitalisation for lower respiratory tract problems in the first 18 months for preterm infants was not reduced [215]. A randomized controlled, trial which included 736 pregnant women and a total of 695 children, showed that the risk of persistent wheeze or asthma was reduced by approximately 7% in the first 5 years of life among children of women who received daily supplementation with omega−3 PUFA (EPA/DHA) during the third trimester of pregnancy. It is notable that this effect was most prominent among children of women with low EPA and DHA blood levels at randomization. Furthermore, supplementation was also associated with a reduced risk of infections of the lower respiratory tract [216]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T321","span":{"begin":0,"end":176},"obj":"Sentence"},{"id":"T322","span":{"begin":177,"end":343},"obj":"Sentence"},{"id":"T323","span":{"begin":344,"end":566},"obj":"Sentence"},{"id":"T324","span":{"begin":567,"end":780},"obj":"Sentence"},{"id":"T325","span":{"begin":781,"end":1115},"obj":"Sentence"},{"id":"T326","span":{"begin":1116,"end":1241},"obj":"Sentence"},{"id":"T327","span":{"begin":1242,"end":1362},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Some studies investigated the effects of the omega-3 fatty acids supplementation on infant morbidity, particularly caused by respiratory tract infections, wheezing, and asthma. Imhoff et al. showed that DHA supplementation during pregnancy decreased the occurrence of colds in children at 1 month and influenced illness symptom duration [213]. Pastor et al. in a multicenter, prospective, open-label observational study, which included 1342 infants, showed a higher incidence of bronchiolitis in control versus groups who received omega-3-supplemented formula [214]. In contrast, in another study aimed to valuate the effect of neonatal DHA supplementation, the hospitalisation for lower respiratory tract problems in the first 18 months for preterm infants was not reduced [215]. A randomized controlled, trial which included 736 pregnant women and a total of 695 children, showed that the risk of persistent wheeze or asthma was reduced by approximately 7% in the first 5 years of life among children of women who received daily supplementation with omega−3 PUFA (EPA/DHA) during the third trimester of pregnancy. It is notable that this effect was most prominent among children of women with low EPA and DHA blood levels at randomization. Furthermore, supplementation was also associated with a reduced risk of infections of the lower respiratory tract [216]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1347","span":{"begin":277,"end":285},"obj":"Species"},{"id":"1348","span":{"begin":441,"end":448},"obj":"Species"},{"id":"1349","span":{"begin":750,"end":757},"obj":"Species"},{"id":"1350","span":{"begin":840,"end":845},"obj":"Species"},{"id":"1351","span":{"begin":865,"end":873},"obj":"Species"},{"id":"1352","span":{"begin":994,"end":1002},"obj":"Species"},{"id":"1353","span":{"begin":1006,"end":1011},"obj":"Species"},{"id":"1354","span":{"begin":1172,"end":1180},"obj":"Species"},{"id":"1355","span":{"begin":1184,"end":1189},"obj":"Species"},{"id":"1356","span":{"begin":688,"end":699},"obj":"Species"},{"id":"1357","span":{"begin":1338,"end":1349},"obj":"Species"},{"id":"1358","span":{"begin":45,"end":64},"obj":"Chemical"},{"id":"1359","span":{"begin":203,"end":206},"obj":"Chemical"},{"id":"1360","span":{"begin":531,"end":538},"obj":"Chemical"},{"id":"1361","span":{"begin":637,"end":640},"obj":"Chemical"},{"id":"1362","span":{"begin":1052,"end":1064},"obj":"Chemical"},{"id":"1363","span":{"begin":1070,"end":1073},"obj":"Chemical"},{"id":"1364","span":{"begin":1207,"end":1210},"obj":"Chemical"},{"id":"1365","span":{"begin":125,"end":153},"obj":"Disease"},{"id":"1366","span":{"begin":169,"end":175},"obj":"Disease"},{"id":"1367","span":{"begin":479,"end":492},"obj":"Disease"},{"id":"1368","span":{"begin":920,"end":926},"obj":"Disease"},{"id":"1369","span":{"begin":1314,"end":1324},"obj":"Disease"}],"attributes":[{"id":"A1347","pred":"tao:has_database_id","subj":"1347","obj":"Tax:9606"},{"id":"A1348","pred":"tao:has_database_id","subj":"1348","obj":"Tax:9606"},{"id":"A1349","pred":"tao:has_database_id","subj":"1349","obj":"Tax:9606"},{"id":"A1350","pred":"tao:has_database_id","subj":"1350","obj":"Tax:9606"},{"id":"A1351","pred":"tao:has_database_id","subj":"1351","obj":"Tax:9606"},{"id":"A1352","pred":"tao:has_database_id","subj":"1352","obj":"Tax:9606"},{"id":"A1353","pred":"tao:has_database_id","subj":"1353","obj":"Tax:9606"},{"id":"A1354","pred":"tao:has_database_id","subj":"1354","obj":"Tax:9606"},{"id":"A1355","pred":"tao:has_database_id","subj":"1355","obj":"Tax:9606"},{"id":"A1356","pred":"tao:has_database_id","subj":"1356","obj":"Tax:12814"},{"id":"A1357","pred":"tao:has_database_id","subj":"1357","obj":"Tax:12814"},{"id":"A1358","pred":"tao:has_database_id","subj":"1358","obj":"MESH:D015525"},{"id":"A1359","pred":"tao:has_database_id","subj":"1359","obj":"MESH:C027493"},{"id":"A1361","pred":"tao:has_database_id","subj":"1361","obj":"MESH:C027493"},{"id":"A1363","pred":"tao:has_database_id","subj":"1363","obj":"MESH:C027493"},{"id":"A1364","pred":"tao:has_database_id","subj":"1364","obj":"MESH:C027493"},{"id":"A1365","pred":"tao:has_database_id","subj":"1365","obj":"MESH:D012141"},{"id":"A1366","pred":"tao:has_database_id","subj":"1366","obj":"MESH:D001249"},{"id":"A1367","pred":"tao:has_database_id","subj":"1367","obj":"MESH:D001988"},{"id":"A1368","pred":"tao:has_database_id","subj":"1368","obj":"MESH:D001249"},{"id":"A1369","pred":"tao:has_database_id","subj":"1369","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Some studies investigated the effects of the omega-3 fatty acids supplementation on infant morbidity, particularly caused by respiratory tract infections, wheezing, and asthma. Imhoff et al. showed that DHA supplementation during pregnancy decreased the occurrence of colds in children at 1 month and influenced illness symptom duration [213]. Pastor et al. in a multicenter, prospective, open-label observational study, which included 1342 infants, showed a higher incidence of bronchiolitis in control versus groups who received omega-3-supplemented formula [214]. In contrast, in another study aimed to valuate the effect of neonatal DHA supplementation, the hospitalisation for lower respiratory tract problems in the first 18 months for preterm infants was not reduced [215]. A randomized controlled, trial which included 736 pregnant women and a total of 695 children, showed that the risk of persistent wheeze or asthma was reduced by approximately 7% in the first 5 years of life among children of women who received daily supplementation with omega−3 PUFA (EPA/DHA) during the third trimester of pregnancy. It is notable that this effect was most prominent among children of women with low EPA and DHA blood levels at randomization. Furthermore, supplementation was also associated with a reduced risk of infections of the lower respiratory tract [216]."}